Generic Name and Formulations:
Imiglucerase 200 Units, 400 Units; per vial; pwd; for IV infusion after reconstitution.
Sanofi Genzyme Company
Indications for CEREZYME:
For long-term enzyme replacement therapy in patients with confirmed Type 1 Gaucher disease that results in one or more of the following conditions: 1) anemia; 2) thrombocytopenia; 3) bone disease; 4) hepatomegaly or splenomegaly.
Adults and Children:
<2yrs: not recommended. ≥2yrs: Give by IV infusion over 1–2 hours. Individualize. Initial dose range: 2.5 Units/kg 3 times a week to 60 Units/kg once every 2 weeks.
Monitor periodically for IgG antibody formation during the first year. Patients previously treated with Ceredase (alglucerase inj) who have developed antibody or hypersensitivity to Ceredase. Monitor for pulmonary hypertension, pneumonia. Pregnancy (Cat.C). Nursing mothers.
GI upset, abdominal pain, rash, pruritus, fatigue, headache, fever, dizziness, chills, backache, tachycardia, inj site reactions, hypersensitivity. Also children: dyspnea, flushing, coughing,
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Neuroimaging Markers of Bipolar Disorder Risk for At-Risk Youth
- Suicide Attempt Risk Among LGB Populations Higher Than Previously Estimated
- Residents Should Take Advantage of Paid Time Off
- Outpatient Engagement May Lower Suicide Attempts in Patients With Fibromyalgia
- Prevalence of Alzheimer Disease, Related Dementia Set to Double